Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05298124 · ClinicalTrials.gov registry record · NA

Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock

A NA study of Mitral Regurgitation and Cardiogenic Shock, sponsored by Ottawa Heart Institute Research Corporation.

Recruiting
Registry status
NA
Development phase
144
Enrollment target
4
Study locations

NCT05298124: Recruiting NA study of Mitral Regurgitation and Cardiogenic Shock, sponsored by Ottawa Heart Institute Research Corporation.

NCT05298124 is a NA study of Mitral Regurgitation and Cardiogenic Shock that is actively recruiting participants, run by Ottawa Heart Institute Research Corporation. The registered enrollment target is 144 participants, below the 1,019-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05298124, a NA study of Mitral Regurgitation and Cardiogenic Shock, is actively recruiting participants, sponsored by Ottawa Heart Institute Research Corporation.

RECRUITING
Registry status
NA
Development phase
144 participants
Enrollment target
4
Study locations

Study Summary

Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock. This study will be a multicenter, open-label, randomized-controlled trial with two study arms: medical therapy and TEER. Patients admitted to the Cardiac Intensive Care Unit (CICU), Cardiac Surgery Intensive Care Unit (CSICU) or Intensive Care Units (ICU) at participating centers will be recruited. The study aims to answer the question: "Does TEER in patients with SCAI stage C or D cardiogenic with concomitant moderate or greater mitral regurgitation improve outcomes as compared to medical therapy?" The study hypothesis is that TEER will lead to an overall improvement in the composite outcome as compared to the medical therapy arm.

Primary Outcome

The primary outcome in this clinical trial will be a composite of in-hospital all-cause mortality, cardiac transplantation, implantation of durable LVAD, or discharge on palliative inotropic therapy.

Interventions

  • DEVICE Transcatheter edge-to-edge repair
  • OTHER Medical therapy

Study Locations (4)

Ontario

  • University of Ottawa Heart Institute - Ottawa
  • Sunnybrook Hospital - Toronto
  • St. Michael's Hospital - Toronto

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2022-05-26
Est. Completion 2025-12
Phase NA

What NCT05298124 shows while recruiting

NCT05298124 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 1,019-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (86% lower).

The record links to 2 conditions, with Mitral Regurgitation appearing as the primary indexed condition, and to 2 interventions - of which Transcatheter edge-to-edge repair is the first listed.

NCT05298124 reports a single indexed study location in Ontario, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05298124 about?

NCT05298124 is a clinical study titled "Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock". Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setti...

What is the current status of trial NCT05298124?

This trial is currently recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2022-05-26. Estimated completion is 2025-12.

What conditions does trial NCT05298124 study?

This clinical trial studies the following conditions: Mitral Regurgitation, Cardiogenic Shock.

What interventions are being tested in trial NCT05298124?

The interventions under investigation include: Transcatheter edge-to-edge repair (DEVICE), Medical therapy (OTHER).

Who is sponsoring clinical trial NCT05298124?

This trial is sponsored by Ottawa Heart Institute Research Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05298124 being conducted?

This trial has 4 study locations across Minnesota, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mitral Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05298124's enrollment target sits among peer trials

144 15th of 26 higher than 12 of 26 other Mitral Regurgitation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mitral Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05298124, the US trial registry maintained by the National Library of Medicine. NCT05298124 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.